To prepare diagnostics industry executives for radically different operating climates and reduce surprises, Venture Planning Group has published a series of 10 global market research surveys, “2017 World In Vitro Diagnostics Industry: Market Shares and Country Forecasts.” The series is designed to provide industry decision-makers with strategically significant competitor information, analyses and insight crucial to the development and implementation of effective business, marketing and R&D programs. The report examines future trends in the U.S., Europe and Asia; reviews over 400 current and emerging assays; analyzes potential applications of innovative technologies; provides supplier shares and sales forecasts by assay, method, market segment, and country; profiles leading players and potential market entrants; and suggests alternative market expansion strategies for instrument and reagent suppliers. The series is based on the following studies:
- Future Scenarios of the In Vitro Diagnostics Market:
Technological Breakthroughs, Economic Austerity, Business-as-Usual
- Opportunities in the Global Clinical Chemistry and Immunodiagnostics:
Spot Fast-Growing Market Segments
Therapeutic Drug Monitoring (TDM), Endocrine Function, Tumor Markers, Special Chemistry,
Immunoproteins, Drugs of Abuse
- Analysis of the Global Molecular Diagnostics Market
Integrating New Technology Planning with Business and Corporate Strategies--
Emerging Tests, Market Forecasts, Competitive Intelligence
- Automated Microbiology Market
Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture,
Urine Screening, Immunodiagnostics
- Infectious Disease Testing: A Rapidly Growing and Challenging Market
Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence
- Market Segmentation Analysis of the Global Cancer Diagnostics Industry:
Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical
Stains--Hospitals, Commercial Labs, POC Locations
- Analysis of the Global Hematology and Flow Cytometry Markets:
France, Germany, Italy, Japan, Spain, UK, USA Sales Forecasts, Supplier Shares,
Competitive Strategies
- Molecular Blood Typing, Grouping and Infectious Disease NAT Market:
France, Germany, Italy, Japan, Spain, UK, US--Emerging Technologies, Sales Forecasts,
Supplier Shares, Competitive Strategies
- New Frontiers in Coagulation Testing:
Global Challenges, Emerging Technologies, Competitive Landscape
- Analysis of the Global Point-of-Care Diagnostic Testing Market
Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies,
Growth Opportunities
Report Highlights
Worldwide Market Overview
- Facilities performing diagnostic tests by country.
- Test volume and sales projections by country.
Market Segmentation Analysis
- Comprehensive review of the market
dynamics, trends, structure, size, growth,
and key suppliers, by country.
- Test volume and sales forecasts for over 400 diagnostic procedures.
- Market segments analyzed in the report include:
- Clinical Chemistry
- Immunodiagnostics
° TDM
° Endocrine Function
° Special Chemistry
° Immunoproteins
° Drugs of Abuse
- Molecular Diagnostics
° Infectious Diseases
° Cancer
° Genetic Testing
° Forensic Testing
° Paternity Testing/HLA Typing
- Microbiology
° Microbial Identification
° Antibiotic Susceptibility
° Urine Screening
° Blood Culture
- Cancer Diagnostic
- Hematology
- Flow Cytometry
- Blood Typing, Grouping, and Screening
- Coagulation Testing
- Centralized Testing Locations
° Hospitals
° Commercial/Private Laboratories
° Public Health Laboratories
° Blood Banks
- POC/Decentralized Testing Locations
° Home/Personal Testing
° Physician Offices/Group Practices
° Emergency Rooms
° Operating/Recovery Suites
° ICUs/CCUs
° Cancer Clinics
° Ambulatory Care Centers
° Surgery Centers
° Nursing Homes
° Birth Centers
Emerging Tests and Instrumentation
- Analysis of current and emerging tests.
- Review of latest instrumentation technologies, and feature
comparison of high-, medium-, and low-volume/POC analyzers.
Technology Review
- Assessment of current and emerging diagnostic technologies,
and their potential market applications.
- Worldwide listings of companies developing
or marketing new technologies and products by test.
Strategic Recommendations
- New product development opportunities
with significant market appeal.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
Competitive Assessments
- Strategic assessments of major diagnostic product
manufactures and emerging market entrants, including
their sales, product portfolios, marketing tactics,
collaborative arrangements and new products in R&D.
The companies analyzed in the report include:
- Abbott
- ADI/America Diagnostica
- AdnaGen/Alere
- Affymetrix
- Agilent Technologies
- Alere/Biosite/Inverness
- Applied Gene Technologies
- Arca Biopharma
- Axis-Shield
- Bayer Healthcare
- Beckman Coulter/Danaher
- Becton Dickinson
- Bio/Data
- Biokit
- Biomedical Diagnostics
- Biomerieux
- Bio-Rad
- Biotest
- Cellavision
- CellMark Forensics/LabCorp
- Cepheid
- Chrono-Log
- Corgenix Medical
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagast
- Diagnocure
- Diagnostica Stago
- Diamedix
- Diasorin
- Eiken Chemical
- EKF Diagnostics
- Elitech Group
- Enzo Biochem
- Enterix
- Epigenomics
- Exact Sciences
- Fujirebio
- Gen-Probe/Hologic
- Grifols
- Guided Therapeutics
- Helena Laboratories
- Horiba
- Hyphen BioMed
- ID Biomedical/GSK
- Illumina
- Immucor
- Instrumentation Laboratory
- International Technidyne/Nexus DX
- Iris Diagnostics/Danaher
- Kreatech/Leica
- Kyowa Medex
- Li-Cor Biosciences
- Lonza
- Mackay Life Sciences
- Matritech/Alere
- Monogram Biosciences/LabCorp
- Myriad Genetics
- Nihon Kohden
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Perkin Elmer/Caliper
- Polartechnics
- Polymedco
- PreMD
- Proteome Sciences
- Qiagen
- Quest Diagnostics
- Quidel
- Radiant Pharmaceuticals
- Roche
- Scienion
- SDIX
- Sequenom
- SeraCare
- Shimadzu
- Siemens
- Sienco
- Sierra Molecular
- Sysmex
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Tecan Group
- Thermo Fisher
- Tosoh
- Trinity Biotech
- Veridex
- Wako
- Wallac/PE
- Zycare/Alere
- Zyla
Methodology
The report is based on a combination of primary and secondary information sources,
including questionnaire responses, as well as interviews with laboratory directors
and executives of leading diagnostic companies and start-up firms developing
innovative technologies and products in the U.S., Europe and Asia.
In addition to primary sources of information, a comprehensive review of
Venture Planning Group’s proprietary database, and the most recent technical,
business, manufacturer, and financial publications was conducted.
Contains approximately 9,700 pages and 3,200 tables